LB Pharmaceuticals appoints Kaya Pai Panandiker as Chief Commercial Officer

LB PHARMACEUTICALS INC

Effective Nov 10, 2025; Panandiker previously CCO at Neumora Therapeutics.
She led commercial at Cerevel (acquired by AbbVie) and was GM Neuroscience at Lundbeck.
Oversaw launches of REXULTI, TRINTELLIX, and ABILIFY MAINTENA (blockbuster sales).
Will lead commercialization of lead candidate LB-102 for schizophrenia and bipolar depression.
Company intends to grant her an inducement equity award outside its 2025 Equity Incentive Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.